Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies

Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D

Tata 1mg-backed 5C Network launches diagnostics-on-demand platform Prodigi PASS

5C Network’s groundbreaking platform aims to bring together diagnostic facilities and healthcare aggregators on a single platform to deliver an unparalleled patient experience

Lonza launches TheraPEAK T-VIVO cell culture medium to accelerate cell therapy development

Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing

Venus Remedies gets Kenyan GMP certification for its manufacturing facilities in Baddi

The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans

Roche introduces navify sample tracking for labs to track patient test samples

navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.

Zydus receives final approval from the USFDA for Ephedrine Sulfate Injection

Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States

Thermo Fisher Scientific expands ImmunoCAP test availability across U.S.

Testing supporting allergy diagnosis now accessible to more people in more communities

Takeda to strengthen health system for rare diseases in India

These initiatives aim to improve access to healthcare for rare disease patients

Philips’ image-guided navigation increases safety during coronary interventions

Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3%